EP Patent

EP4171512B1 — Oral liquid formulations of ruxolitinib

Assigned to Novartis AG · Expires 2026-01-28 · 0y expired

What this patent protects

Patent listed against Tegretol.

Drugs covered by this patent

Tegretol (carbamazepine) · Novartis AG (originally Geigy)

Patent Metadata

Patent number: EP4171512B1
Jurisdiction: EP
Classification: —
Expires: 2026-01-28
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.